Preoperative Radiotherapy versus postoperative Radiotherapy after neoadjuvant Chemotherapy ("NeoRad") in High-risk Breast Cancer: a prospective, randomized, international multicenter Phase III Study

被引：0
作者：
Matuschek, Christiane [1 ]
Jazmati, Danny [2 ]
Krug, David [3 ]
Corradini, Stefanie [4 ]
Fehm, Tanja [5 ]
Ruckhaeberle, Eugen [5 ]
Kuehn, Thorsten [6 ]
Stickeler, Elmar [7 ]
Nestle-Kraemling, Carolin [8 ]
Holtschmidt, Johannes [9 ]
Nekljudova, Valentina [9 ]
Loibl, Sibylle [9 ]
Budach, Wilfried [2 ]
机构：
[1] Univ Bielefeld, Med Fak,Univ klin OWL, Univ klin Strahlentherapie & Radioonkol, Campus Klin Bielefeld, Teutoburger Str 50, D-33604 Bielefeld, Germany
[2] Heinrich Heine Univ Dusseldorf, Med Fak, Klin Strahlentherapie & Radiol Onkol, Dusseldorf, Germany
[3] Univ klin Hamburg Eppendorf, Klin Strahlentherapie, Klin Strahlentherapie & Radioonkol, MVZ, Hamburg, Germany
[4] LMU Munchen, Klin Radioonkol, Munich, Germany
[5] Univ klin Dusseldorf, Med Fak, Frauenklin, CIO ABCD, Dusseldorf, Germany
[6] Filderklin Stuttgart, Stuttgart, Germany
[7] Uniklin Aachen, Frauenklin, CIO ABCD, Aachen, Germany
[8] EVK Dusseldorf, Dusseldorf, Germany
[9] German Breast Grp, Neu Isenburg, Germany
来源：
ONKOLOGIE | 2024年 / 30卷 / 09期
关键词：
Brustkrebs; Bestrahlung; Neoadjuvanz; Krankheitsfreies uberleben; Nebenwirkungen; RADIATION-THERAPY;
D O I：
10.1007/s00761-024-01568-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：840 / 844
页数：5
相关论文
共 50 条
  • [31] Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial
    Liang, J.
    Bi, N.
    Wu, S.
    Chen, M.
    Lv, C.
    Zhao, L.
    Shi, A.
    Jiang, W.
    Xu, Y.
    Zhou, Z.
    Wang, W.
    Chen, D.
    Hui, Z.
    Lv, J.
    Zhang, H.
    Feng, Q.
    Xiao, Z.
    Wang, X.
    Liu, L.
    Zhang, T.
    Du, L.
    Chen, W.
    Shyr, Y.
    Yin, W.
    Li, J.
    He, J.
    Wang, L.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 777 - 783
  • [32] Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
    Lee, W. Robert
    Dignam, James J.
    Amin, Mahul B.
    Bruner, Deborah W.
    Low, Daniel
    Swanson, Gregory P.
    Shah, Amit B.
    D'Souza, David P.
    Michalski, Jeff M.
    Dayes, Ian S.
    Seaward, Samantha A.
    Hall, William A.
    Nguyen, Paul L.
    Pisansky, Thomas M.
    Faria, Sergio L.
    Chen, Yuhchyau
    Koontz, Bridget F.
    Paulus, Rebecca
    Sandler, Howard M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (20) : 2325 - U39
  • [33] Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial
    Wang, Shu-Lian
    Fang, Hui
    Song, Yong-Wen
    Wang, Wei-Hu
    Hu, Chen
    Liu, Yue-Ping
    Jin, Jing
    Liu, Xin-Fan
    Yu, Zi-Hao
    Ren, Hua
    Li, Ning
    Lu, Ning-Ning
    Tang, Yu
    Tang, Yuan
    Qi, Shu-Nan
    Sun, Guang-Yi
    Peng, Ran
    Li, Shuai
    Chen, Bo
    Yang, Yong
    Li, Ye-Xiong
    LANCET ONCOLOGY, 2019, 20 (03) : 352 - 360
  • [34] Definitive external-beam radiotherapy versus radical prostatectomy in clinically localized high-risk prostate cancer: a retrospective study
    Andic, Fundagul
    Izol, Volkan
    Gokcay, Serkan
    Arslantas, Hasan Suat
    Bayazit, Yildirim
    Coskun, Hatice
    Tansug, Mustafa Zuhtu
    Sertdemir, Yasar
    BMC UROLOGY, 2019, 19 (1)
  • [35] Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer
    Boorjian, Stephen A.
    Karnes, R. Jeffrey
    Viterbo, Rosalia
    Rangel, Laureano J.
    Bergstralh, Eric J.
    Horwitz, Eric M.
    Blute, Michael L.
    Buyyounouski, Mark K.
    CANCER, 2011, 117 (13) : 2883 - 2891
  • [36] A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma
    Schmitt, Thomas
    Lehner, Burkhard
    Kasper, Bernd
    Bischof, Marc
    Roeder, Falk
    Dietrich, Sascha
    Dimitrakopoulou-Strauss, Antonia
    Strauss, Ludwig G.
    Mechtersheimer, Gunhild
    Wuchter, Patrick
    Ho, Anthony D.
    Egerer, Gerlinde
    BMC CANCER, 2011, 11
  • [37] Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival
    Casas, F.
    Valduvieco, I.
    Oses, G.
    Izquierdo, L.
    Archila, I.
    Costa, M.
    Cortes, K. S.
    Barreto, T.
    Ferrer, F.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (03) : 355 - 362
  • [38] Physical exercise for functional capacity, blood immune function, fatigue, and quality of life in high-risk prostate cancer patients during radiotherapy: a prospective, randomized clinical study
    Hojan, Katarzyna
    Kwiatkowska-Borowczyk, Eliza
    Leporowska, Ewa
    Gorecki, Maciej
    Ozga-Majchrzak, Owidia
    Milecki, Tomasz
    Milecki, Piotr
    EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE, 2016, 52 (04) : 489 - 501
  • [39] Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design
    Ferris, Robert L.
    Mehanna, Hisham
    Schoenfeld, Jonathan D.
    Tahara, Makoto
    Yom, Sue S.
    Haddad, Robert
    Koenig, Andre
    Witzler, Pauline
    Bajars, Marcis
    Le Tourneau, Christophe
    FUTURE ONCOLOGY, 2024, 20 (12) : 739 - 748
  • [40] Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
    Baumert, Brigitta G.
    Hegi, Monika E.
    van den Bent, Martin J.
    von Deimling, Andreas
    Gorlia, Thierry
    Hoang-Xuan, Khe
    Brandes, Alba A.
    Kantor, Guy
    Taphoorn, Martin J. B.
    Ben Hassel, Mohamed
    Hartmann, Christian
    Ryan, Gail
    Capper, David
    Kros, Johan M.
    Kurscheid, Sebastian
    Wick, Wolfgang
    Enting, Roelien
    Reni, Michele
    Thiessen, Brian
    Dhermain, Frederic
    Bromberg, Jacoline E.
    Feuvret, Loic
    Reijneveld, Jaap C.
    Chinot, Olivier
    Gijtenbeek, Johanna M. M.
    Rossiter, John P.
    Dif, Nicolas
    Balana, Carmen
    Bravo-Marques, Jose
    Clement, Paul M.
    Marosi, Christine
    Tzuk-Shina, Tzahala
    Nordal, Robert A.
    Rees, Jeremy
    Lacombe, Denis
    Mason, Warren P.
    Stupp, Roger
    LANCET ONCOLOGY, 2016, 17 (11) : 1521 - 1532
12345